Teleflex Incorporated (TFX)
400.39 -1.00 (-0.25%)
After hours: 4:09PM EST
Chart Events
Performance Outlook
| Previous Close | 395.15 |
| Open | 392.87 |
| Bid | 400.57 x 1300 |
| Ask | 401.09 x 800 |
| Day's Range | 396.50 - 403.76 |
| 52 Week Range | 221.27 - 414.72 |
| Volume | 166,644 |
| Avg. Volume | 201,854 |
| Market Cap | 18.645B |
| Beta (5Y Monthly) | 1.21 |
| PE Ratio (TTM) | 51.53 |
| EPS (TTM) | 7.77 |
| Earnings Date | Feb 25, 2021 |
| Forward Dividend & Yield | 1.36 (0.35%) |
| Ex-Dividend Date | Nov 12, 2020 |
| 1y Target Est | 445.09 |
- GlobeNewswire
Teleflex Announces Submission of Biologics License Application for Its Investigational Freeze Dried Plasma
Submission is eligible for priority review and accelerated approvalWAYNE, Pa., Feb. 24, 2021 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies for critical care and surgery, has announced it has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for its investigational freeze dried plasma (FDP) candidate. The investigational FDP is a lyophilized (freeze dried) unit of human plasma being developed under a Cooperative Research and Development Agreement (CRADA) with the U.S. Army Medical Materiel Development Activity (USAMMDA). The investigational FDP is subject to the amendments made to section 564 of the Federal Food, Drug, and Cosmetic Act under H.R 4374 [Public Law No: 115-92]. This law allows for authorization of additional emergency uses for medical products to reduce deaths and severity of injuries caused by agents of war.1 “This is an exciting milestone for Teleflex. We look forward to working with the FDA in a timely and efficient manner to address any needs for additional information that may arise,” said Liam Kelly, Chairman, President and Chief Executive Officer of Teleflex. Teleflex’s freeze dried plasma candidate is an investigational new drug and has not yet been approved by the FDA. About Teleflex IncorporatedTeleflex is a global provider of medical technologies designed to improve the health and quality of people’s lives. We apply purpose driven innovation – a relentless pursuit of identifying unmet clinical needs – to benefit patients and healthcare providers. Our portfolio is diverse, with solutions in the fields of vascular access, interventional cardiology and radiology, anesthesia, emergency medicine, surgical, urology and respiratory care. Teleflex employees worldwide are united in the understanding that what we do every day makes a difference. For more information, please visit teleflex.com. Teleflex is the home of Arrow®, Deknatel®, Hudson RCI®, LMA®, Pilling®, Rüsch®, UroLift®, and Weck® – trusted brands united by a common sense of purpose. Forward-Looking StatementsAny statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Any forward-looking statements contained herein are based on our management's current beliefs and expectations, but are subject to a number of risks, uncertainties and changes in circumstances, which may cause actual results or company actions to differ materially from what is expressed or implied by these statements. These risks and uncertainties are identified and described in more detail in our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K. Reference: 1. Public Law 115-92, Dec. 12, 2017. Congress.gov. https://www.congress.gov/115/plaws/publ92/PLAW-115publ92.pdf. Accessed January 9, 2021. Teleflex, the Teleflex logo, Arrow, Deknatel, Hudson RCI, LMA, Pilling, Rüsch, UroLift, and Weck are trademarks or registered trademarks of Teleflex Incorporated or its affiliates, in the U.S. and/or other countries.© 2021 Teleflex Incorporated. All rights reserved. MC-007064 Source: Teleflex IncorporatedJake ElguiczeTreasurer and Vice President, Investor Relations610-948-2836
- GlobeNewswire
Teleflex to Present at Barclays Global Healthcare Conference
WAYNE, Pa., Feb. 23, 2021 (GLOBE NEWSWIRE) -- Liam Kelly, Chairman, President and CEO, Teleflex Incorporated (NYSE: TFX), is scheduled to speak at Barclays Global Healthcare Conference on Tuesday, March 9, 2021 at 10:55 am (ET). A live audio webcast of the conference presentation, along with the accompanying slide presentation, will be available on the investor portion of the Teleflex website at www.teleflex.com. About Teleflex IncorporatedTeleflex is a global provider of medical technologies designed to improve the health and quality of people’s lives. We apply purpose driven innovation – a relentless pursuit of identifying unmet clinical needs – to benefit patients and healthcare providers. Our portfolio is diverse, with solutions in the fields of vascular access, interventional cardiology and radiology, anesthesia, emergency medicine, surgical, urology and respiratory care. Teleflex employees worldwide are united in the understanding that what we do every day makes a difference. For more information, please visit teleflex.com. Teleflex is the home of Arrow®, Deknatel®, Hudson RCI®, LMA®, Pilling®, Rüsch®, UroLift®, and Weck® – trusted brands united by a common sense of purpose. Source: Teleflex IncorporatedJake ElguiczeTreasurer and Vice President, Investor Relations610-948-2836
- GlobeNewswire
Teleflex Completes Enrollment in CTO-PCI IDE Study
Enrollment Completed Ahead of Schedule in Study Evaluating the Performance of Teleflex Specialty Catheters and Coronary Guidewires in Patients Undergoing Chronic Total Occlusion Percutaneous Coronary InterventionsWAYNE, Pa., Feb. 17, 2021 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced the completion of patient enrollment in a clinical study evaluating the performance of Teleflex specialty catheters and coronary guidewires in Chronic Total Occlusion (CTO) percutaneous coronary intervention (PCI) procedures—currently an investigational indication for these products. The study enrolled 150 patients across 13 investigational sites in the US and completed enrollment three months ahead of schedule. The CTO-PCI study is a prospective, single-arm IDE study employing the primary angiographic endpoint of successful (intralumenal) guidewire placement beyond the CTO. CTOs are longstanding complete blockages in coronary arteries that result in profound regional reduction of coronary blood flow (ischemia). Clinically significant CTOs are found in nearly 20% of patients undergoing diagnostic coronary angiography for suspected ischemic heart disease.1 Often a source of limiting symptoms, CTOs may also contribute to cardiac dysfunction and are associated with poor prognosis.2 The principal investigators of the study include David E. Kandzari, MD3, Director, Interventional Cardiology and Chief of the Piedmont Heart Institute and Cardiovascular Service Line, Atlanta, GA, and Dimitri Karmpaliotis, MD, Director of CTO, Complex and High-Risk PCI at Columbia University Irving Medical Center. “The fast enrollment in the CTO-PCI study reflects the strong interest in further advancing contemporary techniques in CTO revascularization—the most demanding PCI environment,” said Dr. Kandzari. In addition to measuring procedure success and the absence of major adverse cardiac events (MACE), the study is evaluating the frequency of successful recanalization, frequency of MACE in-hospital and at 30 days post-procedure, frequency of clinically significant perforation, procedural success according to crossing technique, and technical success (defined as successful guidewire recanalization using Teleflex study devices). Enrolling 30 of the 150 patients, Khaldoon Alaswad, MD3, Director, Cardiac Catheterization Laboratory at Henry Ford Hospital, Detroit, MI, was the lead enroller in the study. “The study results will enhance the CTO-PCI skill set and inform interventionalists about the performance of the Teleflex product line in CTO procedures,” said Dr. Alaswad. Study devices include the GuideLiner® V3 catheter, TrapLiner® catheter, Turnpike® catheter, and a series of five coronary guidewires (SpectreTM Guidewire, R350TM Guidewire, RaiderTM Guidewire, WarriorTM Guidewire and BanditTM Guidewire). Each study device is currently commercially available in the US under a more general indication. These products are investigational devices for clinical evaluation as used in the CTO-PCI study. “We are very encouraged by the brisk enrollment in the CTO-PCI IDE study and look forward to the results,” said Teleflex Medical Director, Dr. Christopher Buller. About Teleflex Incorporated Teleflex is a global provider of medical technologies designed to improve the health and quality of people’s lives. We apply purpose driven innovation – a relentless pursuit of identifying unmet clinical needs – to benefit patients and healthcare providers. Our portfolio is diverse, with solutions in the fields of vascular access, interventional cardiology and radiology, anesthesia, emergency medicine, surgical, urology and respiratory care. Teleflex employees worldwide are united in the understanding that what we do every day makes a difference. For more information, please visit teleflex.com. Teleflex is the home of Arrow®, Deknatel®, Hudson RCI®, LMA®, Pilling®, Rusch®, UroLift®, and Weck® – trusted brands united by a common sense of purpose. Forward-Looking Statements Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Any forward-looking statements contained herein are based on our management's current beliefs and expectations, but are subject to a number of risks, uncertainties and changes in circumstances, which may cause actual results or company actions to differ materially from what is expressed or implied by these statements. These risks and uncertainties are identified and described in more detail in our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K. Teleflex, the Teleflex logo, Bandit, GuideLiner, R350, Raider, Spectre, TrapLiner, Turnpike, Warrior, Arrow, Deknatel, Hudson RCI, LMA, Pilling, Rusch, UroLift, and Weck are trademarks or registered trademarks of Teleflex Incorporated or its affiliates, in the U.S. and/or other countries. © 2021 Teleflex Incorporated. All rights reserved. MC-007026 Rev 0.1 References: 1. Fefer, P. et al. Current Perspectives on Coronary Chronic Total Occlusions: The Canadian Multicenter Chronic Total Occlusions CTO Registry. Journal of the American College of Cardiology 2012;59 (11): 991-7. 2. Tajstra, P. et al. Impact of Chronic Total Occlusion of the Coronary Artery on Long-Term Prognosis in Patients With Ischemic Systolic Heart Failure: Insights From the COMMIT-HF Registry. JACC: Cardiovascular Interventions 2016; 9 (17): 1790-97. 3. Drs. Kandzari and Alaswad are paid consultants of Teleflex or its affiliates. Source: Teleflex IncorporatedJake ElguiczeTreasurer and Vice President, Investor Relations610-948-2836
